Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 198.13B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 12.21 |
| Forward PE | 10.54 |
| Dividend | 2.91 (3.58%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 4,750 |
| Average Volume | 3,598 |
| Open | 79.30 |
| Previous Close | 80.50 |
| Day's Range | 78.60 - 81.20 |
| 52-Week Range | 65.50 - 99.40 |
| Beta | 0.32 |
| RSI | 72.74 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Market Today: Stocks Whipsaw, Walmart CEO exits, Merck buys Cidara
Market Today: Stocks Whipsaw, Walmart CEO exits, Merck buys Cidara
Cidara Therapeutics Shares Soar 105% After Merck Agrees To $9.2B Takeover Deal
(RTTNews) - Cidara Therapeutics, Inc. (CDTX) climbed 105.68% to $217.99, up $112.00, after it announced that Merck & Co. will acquire all outstanding shares for $221.50 per share in cash, valuing the ...
Merck Is Paying Up for Flu Biotech as M&A Spree Continues
This is why Merck is buying Cidara Therapeutics for $9.2 billion, and why Wall Street is happy
Merck is facing a patent cliff for Keytruda and upheaval in the market for Gardasil.
Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why
NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX
Nvidia (NVDA) got bullish momentum from Wells Fargo and Morgan Stanley ahead of next week's earnings. Diane King Hall talks about what analysts expect from Nvidia's long-term prospects.
Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal
Cidara Therapeutics shares doubled, and then some, on Friday after Merck agreed to buy the biotech company for $9.2 billion.
Merck Makes Big Bet On Flu Protection With Cidara Buyout
Merck & Co. Inc. (NYSE: MRK) on Friday agreed to acquire Cidara Therapeutics, Inc. (NASDAQ: CDTX) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion . “We con...
4 stocks to watch on Friday: MRK, NU, GAP, BMY
MRK, NU, GAP, BMY are the stocks to watch on Friday
Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approaches
Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion deal, accelerating efforts to broaden its respiratory portfolio as it prepares for the loss of exclusivity on...
Merck (MRK) Acquires Cidara Therapeutics, Boosting Stock Value
Merck (MRK) Acquires Cidara Therapeutics, Boosting Stock Value
Merck (MRK) to Acquire Cidara Therapeutics in Definitive Agreement
Merck (MRK) to Acquire Cidara Therapeutics in Definitive Agreement
Merck (MRK) to Acquire Cidara Therapeutics in $9.2 Billion Deal
Merck (MRK) to Acquire Cidara Therapeutics in $9.2 Billion Deal
Merck to Buy Cidara Therapeutics in $9.2 Billion Deal
Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker's respiratory portfolio.
Merck To Acquire Cidara For $221.50/shr
(RTTNews) - Merck (MRK) and Cidara Therapeutics, Inc. (CDTX) have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a ...
Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent
RAHWAY, N.J. & SAN DIEGO, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”), a biotechnology com...
Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring
Merck (MRK) is close to acquiring Cidara Therapeutics (CDTX) in a deal potentially exceeding $3.3 billion, with announcement expected soon. CDTX shares surged 85% on news of the potential acquisition,...
Cidara Therapeutics (CDTX) Surges on Merck Acquisition Talks
Cidara Therapeutics (CDTX) Surges on Merck Acquisition Talks
Merck (MRK) Nears Acquisition of Cidara Therapeutics (CDTX)
Merck (MRK) Nears Acquisition of Cidara Therapeutics (CDTX)
Merck seen nearing acquisition of Cidara Therapeutics in deal potentially above $3.3 billion
Cidara Therapeutics Shares Surge In After-Hours On Report Of Nearing Merck Deal
(RTTNews) - Merck & Co. Inc. (MRK) is nearing a deal to acquire Cidara Therapeutics (CDTX), a biotechnology company developing a long-acting antibody treatment for influenza, the Financial Times repor...
Merck nearing deal for Cidara, FT reports
Merck is closing in on a deal to buy Cidara Therapeutics in a deal valuing the biotechnology company at a premium to its $3.3 billion market capitalization, the Financial Times reported on Thursday.